BridgeBio to Present Primary Results from Phase 3 PROPEL 3 Trial of Oral Infigratinib for Children Living with Achondroplasia at ICCBH 2026
Go back to BridgeBio to Present Primary Results from Phase 3 PROPEL 3 Trial of Oral Infigratinib for Children Living with Achondroplasia at ICCBH 2026| (NASDAQ: BBIO) | Delayed: 66.30 -0.31 (0.47%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $66.61 | 52 Week High | $ | |||
| Open | $67.01 | 52 Week Low | $ | |||
| Day High | $67.33 | P/E | N/A | |||
| Day Low | $65.78 | EPS | $ | |||
| Volume | 2,013,552 | |||||
